190 related articles for article (PubMed ID: 37884883)
1. Leveraging a disulfidptosis-related signature to predict the prognosis and immunotherapy effectiveness of cutaneous melanoma based on machine learning.
Zhao Y; Wei Y; Fan L; Nie Y; Li J; Zeng R; Li J; Zhan X; Lei L; Kang Z; Li J; Zhang W; Yang Z
Mol Med; 2023 Oct; 29(1):145. PubMed ID: 37884883
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y; Kong X; Mei H; Wang J; Zhou S
Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
[TBL] [Abstract][Full Text] [Related]
3. Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients.
Chen H; Yang W; Li Y; Ma L; Ji Z
Front Immunol; 2023; 14():1198878. PubMed ID: 37325625
[TBL] [Abstract][Full Text] [Related]
4. Machine learning-based signature of necrosis-associated lncRNAs for prognostic and immunotherapy response prediction in cutaneous melanoma and tumor immune landscape characterization.
Cui Z; Liang Z; Song B; Zhu Y; Chen G; Gu Y; Liang B; Ma J; Song B
Front Endocrinol (Lausanne); 2023; 14():1180732. PubMed ID: 37229449
[TBL] [Abstract][Full Text] [Related]
5. Leveraging a gene signature associated with disulfidptosis identified by machine learning to forecast clinical outcomes, immunological heterogeneities, and potential therapeutic targets within lower-grade glioma.
Zhou Y; Cao Y; Liu W; Wang L; Kuang Y; Zhou Y; Chen Q; Cheng Z; Huang H; Zhang W; Jiang X; Wang B; Ren C
Front Immunol; 2023; 14():1294459. PubMed ID: 38162649
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
7. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
Front Immunol; 2022; 13():967277. PubMed ID: 36466837
[TBL] [Abstract][Full Text] [Related]
8. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer.
Liang J; Wang X; Yang J; Sun P; Sun J; Cheng S; Liu J; Ren Z; Ren M
Front Immunol; 2023; 14():1198826. PubMed ID: 38035071
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
10. A novel disulfidptosis-associated expression pattern in breast cancer based on machine learning.
Wang Z; Du X; Lian W; Chen J; Hong C; Li L; Chen D
Front Genet; 2023; 14():1193944. PubMed ID: 37456667
[No Abstract] [Full Text] [Related]
11. Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma.
Zhu Z; Li G; Li Z; Wu Y; Yang Y; Wang M; Zhang H; Qu H; Song Z; He Y
Front Immunol; 2022; 13():914612. PubMed ID: 36072600
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms.
Chi H; Huang J; Yan Y; Jiang C; Zhang S; Chen H; Jiang L; Zhang J; Zhang Q; Yang G; Tian G
Front Mol Biosci; 2023; 10():1254232. PubMed ID: 37916187
[No Abstract] [Full Text] [Related]
13. Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma.
Shen K; Wang Q; Wang L; Yang Y; Ren M; Li Y; Gao Z; Zheng S; Ding Y; Ji J; Wei C; Zhang T; Zhu Y; Feng J; Qin F; Yang Y; Wei C; Gu J
Eur J Med Res; 2023 Sep; 28(1):352. PubMed ID: 37716991
[TBL] [Abstract][Full Text] [Related]
14. Single-cell sequencing and bulk RNA data reveal the tumor microenvironment infiltration characteristics of disulfidptosis related genes in breast cancer.
Chen Y; Jin C; Cui J; Diao Y; Wang R; Xu R; Yao Z; Wu W; Li X
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12145-12164. PubMed ID: 37428249
[TBL] [Abstract][Full Text] [Related]
15. The development and experimental validation of hypoxia-related long noncoding RNAs prognostic signature in predicting prognosis and immunotherapy of cutaneous melanoma.
Wang G; Sun Y; Xu Q
Aging (Albany NY); 2023 Nov; 15(21):11918-11939. PubMed ID: 37921852
[TBL] [Abstract][Full Text] [Related]
16. Single-cell sequencing analysis related to sphingolipid metabolism guides immunotherapy and prognosis of skin cutaneous melanoma.
Ding Y; Zhao Z; Cai H; Zhou Y; Chen H; Bai Y; Liu Z; Liu S; Zhou W
Front Immunol; 2023; 14():1304466. PubMed ID: 38077400
[TBL] [Abstract][Full Text] [Related]
17. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.
Wang Y; Xu Y; Liu C; Yuan C; Zhang Y
Front Immunol; 2023; 14():1233260. PubMed ID: 37799714
[TBL] [Abstract][Full Text] [Related]
18. Establishing a Ten Disulfidptosis-related Gene Signature for Prognostic Prediction in Skin Cutaneous Melanoma.
Li H; Chen Z; Huang Y; Chen C; Cai L
Comb Chem High Throughput Screen; 2024 Jun; ():. PubMed ID: 38879775
[TBL] [Abstract][Full Text] [Related]
19. A Novel Pyroptotic and Inflammatory Gene Signature Predicts the Prognosis of Cutaneous Melanoma and the Effect of Anticancer Therapies.
Xu Y; Chen Y; Niu Z; Xing J; Yang Z; Yin X; Guo L; Zhang Q; Qiu H; Han Y
Front Med (Lausanne); 2022; 9():841568. PubMed ID: 35492358
[TBL] [Abstract][Full Text] [Related]
20. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11157-11170. PubMed ID: 37347261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
